SCHEMBL1007702

SCHEMBL1007702

O=C(O)CCC(=O)c1ccc(OCc2ccccc2C(F)(F)F)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.68
MAOA P21397 1/20 0.68
FFAR4 Q5NUL3 6/20 0.51
FFAR1 O14842 5/20 0.51
SPHK2 Q9NRA0 2/20 0.49
SPHK1 Q9NYA1 2/20 0.49
SRD5A2 P31213 1/20 0.49
PTPRC P08575 1/20 0.49
PTPN1 P18031 1/20 0.49
NR4A2 P43354 2/20 0.47
ADAMTS4 O75173 1/20 0.47
MMP13 P45452 1/20 0.47
ALOX5 P09917 1/20 0.47
ALOX5AP P20292 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 1/20 0.47
EPHX2 P34913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2087299 0.83 MAOB (0.66) MAOBFFAR4FFAR1PTPRCPTPN1
SCHEMBL2088377 0.81 MAOB (1.00) MAOBMAOASPHK2SPHK1SRD5A2
SCHEMBL1008781 0.80 NR4A2 (0.72) MAOBMAOAFFAR4FFAR1PTPRC
SCHEMBL4759812 0.80 MAOB (0.65) MAOBMAOAFFAR4FFAR1ADAMTS4
SCHEMBL2086626 0.80 MAOB (0.68) MAOBFFAR4FFAR1PTPRCPTPN1
SCHEMBL1007847 0.78 L3MBTL1 (0.65) FFAR4FFAR1PTPRCPTPN1NR4A2
SCHEMBL958582 0.78 EGFR (0.69) MAOBFFAR4FFAR1SRD5A2NR4A2
SCHEMBL12423202 0.74 MAOB (0.68) MAOBMAOAFFAR4FFAR1SPHK2
SCHEMBL365767 0.74 MAOB (0.67) MAOBMAOASPHK2SPHK1SRD5A2
SCHEMBL2086520 0.74 FFAR1 (0.50) MAOBFFAR4FFAR1NR4A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461323-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2013-10-09 EP claimed
JP-4711621-B2 2011-06-29 JP claimed
CN-100344616-C Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORP (US) 2007-10-24 CN claimed
US-7101910-B2 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2006-09-05 US claimed
CN-1608055-A Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORP (US) 2005-04-20 CN claimed
EP-1461323-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2004-09-29 EP claimed
US-20030149107-A1 Compounds for the treatment of metabolic disorders PHARMA CINQ, LLC 2003-08-07 US claimed
WO-2002100341-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2002-12-19 WO claimed
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9133073-B2 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2015-09-15 US disclosed
US-9133073-B2 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2015-09-15 US disclosed
US-9133073-B2 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2015-09-15 US disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-20040097585-A1 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION 2004-05-20 US disclosed
US-20040092516-A1 Compounds for the treatment of metabolic disorders PHARMA CINQ, LLC 2004-05-13 US disclosed
US-20040092518-A1 Compounds for the treatment of metabolic disorders PHARMA CINQ, LLC 2004-05-13 US disclosed
US-20040077896-A1 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION 2004-04-22 US disclosed
US-20030149107-A1 Compounds for the treatment of metabolic disorders PHARMA CINQ, LLC 2003-08-07 US disclosed
WO-2002100341-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092516-A1 Compounds for the treatment of metabolic disorders GOT2, OAT, CPT1B MAOB 589/4885MAOA 1265/4885FFAR4 71/4885
US-20040092518-A1 Compounds for the treatment of metabolic disorders GOT2, OAT, CPT1B MAOB 589/4885MAOA 1265/4885FFAR4 71/4885
US-20040097585-A1 Compounds for the treatment of metabolic disorders GOT2, OAT, CPT1B MAOB 589/4885MAOA 1265/4885FFAR4 71/4885
US-20040077896-A1 Compounds for the treatment of metabolic disorders GOT2, OAT, CPT1B MAOB 589/4885MAOA 1265/4885FFAR4 71/4885
US-20030149107-A1 Compounds for the treatment of metabolic disorders GOT2, OAT, CPT1B MAOB 589/4885MAOA 1265/4885FFAR4 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.